BioMarin: Why I See Significant Upside Into 2027

BioMarin raised its full-year 2026 revenue guidance floor by $50 million, to $3.88 billion-$3.93 billion from $3.83 billion-$3.93 billion. Key upcoming catalysts include Phase 1/2 data for 12 mg/kg BMN 351 in Duchenne muscular dystrophy by year-end 2026 and a potential H1 2027 approval of Voxzogo for hypochondroplasia.

Analysis

The guidance increase is too small to change FY26 valuation on its own; the investable issue is whether it signals durable uptake across the commercial portfolio rather than a one-quarter timing benefit. BMRN’s multiple can re-rate over the next 1-3 months if upcoming results demonstrate that incremental revenue converts to operating leverage, with gross-to-net trends and selling-expense discipline more important than the headline beat. A guidance raise without a corresponding lift in implied exit-rate growth would likely be treated as de-risking rather than a new earnings-growth leg.

BMN 351 is the higher-beta catalyst because a small, uncontrolled early dataset can move BMRN materially in either direction before the market has a clean probability-of-success framework. Functional durability, dose-limiting safety, immunogenicity, and evidence of differentiation versus the DMD standard of care matter more than biomarker movement; weak durability could also pressure the perceived value of BioMarin’s broader rare-disease development engine. Positive data would strengthen strategic optionality, while an equivocal readout is more likely to produce a sharp drawdown than modest underperformance given the scarcity premium investors assign to credible DMD assets.

The H1 2027 hypochondroplasia decision is a cleaner medium-term earnings catalyst, but approval alone is insufficient: the market will focus on label breadth, payer restrictions, and the pace at which diagnosis and treatment expansion translate into treated patients. Contrarian view: expectations may be underpricing a benign regulatory outcome but overpricing immediate launch revenue, since pediatric rare-disease adoption can be constrained by referral pathways and reimbursement even with strong physician demand. The key falsifier for a bullish thesis is not approval timing but 2027 guidance that fails to show meaningful contribution from new-patient starts and sustained operating-margin expansion.

Key Decisions for Investors

• Maintain or initiate a modest long BMRN into the year-end BMN 351 update only if position sizing assumes binary clinical risk; target a 6-12 month holding period, with upside tied to credible functional durability rather than a biomarker-only signal. Reduce exposure ahead of the readout if the stock materially outperforms rare-disease peers without new efficacy disclosure.
• Use a defined-risk upside structure for the BMN 351 event, such as a call spread spanning the data window, rather than outright short-dated calls; implied volatility should be checked against the expected post-data move before entry. The trade is unattractive if event volatility already prices a move exceeding a plausible favorable-data re-rating.
• For a lower-volatility expression, pair long BMRN against short XBI over the next 3-6 months, contingent on BMRN maintaining revenue-growth and margin execution. This isolates company-specific commercial and regulatory de-risking from broad biotech beta; exit if BMRN cuts 2027 operating-margin expectations or the Phase 1/2 safety profile introduces a program hold risk.
• Set a post-approval watch item for Voxzogo: add only after label language and initial payer-access disclosures establish addressable population and utilization. A restrictive label, onerous prior authorization, or weak early prescription conversion would invalidate the thesis that regulatory success translates rapidly into earnings acceleration.